Van Dijk H, Rapis M, Jacobse-Geels H E, Willers J M
Clin Exp Immunol. 1979 Mar;35(3):470-7.
Tolazoline, a drug used in the treatment of hypertension, has been described as a typical H2 agonist. In this study possible immunomodulating properties of tolazoline were investigated. A single injection of tolazoline 1 day before immunization caused an effect on delayed hypersensitivity that depended on the antigen dose. The response to 10(5) and 10(6) sheep red blood cells (SRBC) was decreased, whereas the response to 10(9) SRBC was enhanced. Administration of tolazoline 4 days after immunization predominantly affected the humoral response. The IgM response was inhibited in favour of the IgG response. Low doses of tolazoline, given to animals simultaneously with the elicitation for delayed hypersensitivity, lead to a more severe inflammation. The possible involvement of suppressor cells and vessels in tolazoline action is discussed. The application of tolazoline in the immunotherapy of human cancer is suggested.
妥拉唑啉是一种用于治疗高血压的药物,被描述为典型的H2激动剂。在本研究中,对妥拉唑啉可能的免疫调节特性进行了研究。免疫前1天单次注射妥拉唑啉对迟发型超敏反应产生了影响,该影响取决于抗原剂量。对10(5)和10(6)个绵羊红细胞(SRBC)的反应降低,而对10(9)个SRBC的反应增强。免疫后4天给予妥拉唑啉主要影响体液反应。IgM反应受到抑制,有利于IgG反应。在引发迟发型超敏反应的同时给动物低剂量的妥拉唑啉,会导致更严重的炎症。讨论了抑制细胞和血管可能参与妥拉唑啉的作用。建议将妥拉唑啉应用于人类癌症的免疫治疗。